Litcius/Paper detail

A new immuno-oncology target – SUMOylation

Yuan Chen

2023Trends in cancer24 citationsDOIOpen Access PDF

Abstract

Immunotherapy has been a paradigm shift in cancer treatment to produce durable responses. Unfortunately, most cancers do not respond to current immunotherapies, and thus, exploring novel mechanisms is crucial. Emerging data now demonstrate that protein modification by the small ubiquitin-like modifiers (SUMO) is a novel target to activate antitumor immunity.

Topics & Concepts

SUMO proteinImmunotherapyImmune systemBiologyCancer immunotherapyCancer researchImmunologyUbiquitinGeneGeneticsUbiquitin and proteasome pathwaysPeptidase Inhibition and AnalysisImmunotherapy and Immune Responses
A new immuno-oncology target – SUMOylation | Litcius